1. Ho M, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746–50.
2. US Food and Drug Administration. Patient preference information – voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling, issued August 2016. (
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM446680.pdf
).
3. European Medicines Agency. The Patient’s Voice in the Evaluation of Medicines: How Patients Can Contribute to Assessment of Benefit and Risk, issued October 2013. (
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/10/WC500153276.pdf
).
4. Danner M, et al. Integrating patients' views into health technology assessment: analytic hierarchy process (HAP) as a method to elicit patient preferences. Int J Technol Assess Health Care. 2011;27(4):369–75.
5. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: Oxford university press; 2015.